Prevention of diet-induced hepatic steatosis and hepatic insulin resistance by second generation antisense oligonucleotides targeted to the longevity gene mIndy (Slc13a5)
Figure 2.
(A) 4 weeks of mIndy ASO treatment resulted in a 25% reduction in liver triglycerides and (B) a 35% reduction in plasma triglycerides. All data are mean ± SEM, N=10 for each group; significances by double sided t-test